Malaysia-based BioNexus Gene Lab has announced its treasury strategy, prioritizing Ethereum (ETH) over Bitcoin (BTC). The company cited Ethereum's recent inclusion in the US Crypto Strategic Reserve and its broader utility as a programmable financial platform as reasons for its decision. BioNexus also highlighted Ethereum's institutional adoption, staking potential, and dominance in DeFi as supporting factors. The company aims to become the first Nasdaq-listed firm to adopt an Ethereum-exclusive treasury strategy. BioNexus also mentioned Wyoming's blockchain-friendly regulatory environment and the Wyoming Stable Token Act as additional factors. The company believes Ethereum's staking mechanism, role in global finance, and various financial solutions make it an attractive option for treasury management. It expects mainstream financial acceptance and an increase in Ethereum ETF adoption by corporations. Integration with Ethereum aligns BioNexus with the evolution of corporate finance and the ongoing upgrades to the Ethereum network, including the upcoming Pectra update.



Other News from Today